HALIFAX, NOVA SCOTIA — November 29, 2025 — Leads & Copy — MedMira Inc. (TSXV:MIR) has released its financial results for the year ended July 31, 2025, along with a corporate update.
The company launched its Health Canada-approved Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) and the latest generation of its Reveal® Rapid HIV Test in Canada during fiscal year 2025. Following the fiscal year end, Health Canada also approved MedMira’s Reveal® TP (Syphilis) rapid test, which the company claims is the fastest Syphilis antibody test available in Canada. Provincial validation, supported by MedMira’s partners, has been completed and implementation with various provincial buying groups has begun.
In the United States, MedMira achieved VA and Federal listing, which the company said is a major step toward securing multi-year contracts and awards from those organizations. The company expanded its distribution network in fiscal year 2025 with specialized partners focused on VA, Federal, and State contracts. MedMira said these achievements enhance its sales capabilities with established and preferred partners in the U.S.
Despite delays related to the changing environment in the U.S. during the first part of 2025, the company reported steady progress during the second half of the year. Through its partners, MedMira bid on contracts using its FDA-approved Reveal® G4 HIV-1/2 rapid test. Award and contract details will be released when issued by the customers. MedMira anticipates that a future FDA CLIA waiver will provide further access to more contracts and increase overall sales opportunities.
MedMira successfully completed the first phase of clinical trials in Canada for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). An independent publication outlining the product’s performance and positive impact is expected in early December 2025. The company began the second phase of the clinical trial, expecting completion in early Q1 2026. In conjunction with its partners, MedMira also started clinical trials for self-testing using its Multiplo® TP/HIV rapid test in Canada.
MedMira, along with its partners, is working on a structure to accelerate the commercial version of MedMira’s MiROQ technology. The patented diagnostic system allows for efficient diagnostic tools that provide quantitative results in minutes. The company believes this technology could significantly impact faster and more reliable cancer diagnoses. MedMira is currently working on the commercial prototype and software development, which will include AI as a supporting element for future diagnostics. The company said this strategic partnership will fast-track technology development and allow earlier market access. MedMira maintains that MiROQ enhances its RVF Technology and provides the opportunity to expand its product offerings and market access.
The company reported the following profit and loss highlights:
- Revenue: $240,509 in FY2025, compared to $412,568 in FY2024.
- Gross Profit: $172,851 in FY2025, compared to $226,489 last year.
- Operating Expenses: $3,762,598 in FY2025, compared to $2,799,485 in FY2024.
- Net Loss: $4,524,407 in FY2025, compared to $3,326,321 in FY2024.
Balance sheet highlights include:
- Assets decreased by $2,387,859.
- Liabilities increased by $2,136,548, or 9%.
- Loans in default decreased by $192,374.
- Working Capital deficit increased to $3,141,511, or 18%.
The company’s financial statements and management’s discussion and analysis are available on SEDAR at www.sedar.com.
Markus Meile, CFO, can be reached at 902-450-1588 or ir@medmira.com.
Source: MedMira, Inc.
